Drug Screening of Patient-Derived Organoids from Colorectal Peritoneal Metastases

Cancer statistics, 2019

R. Siegel, K. D. Miller, A. Jemal. (2019). CA: A Cancer Journal for Clinicians. Cited 18,104 times. https://doi.org/10.3322/caac.21551

Comprehensive molecular characterization of human colon and rectal cancer

D. Muzny, M. Bainbridge, K. Chang, et al.. (2012). Nature. Cited 7,495 times. https://doi.org/10.1038/nature11252

Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

P. Chapman, A. Hauschild, C. Robert, et al.. (2011). The New England journal of medicine. Cited 6,731 times. https://doi.org/10.1056/NEJMoa1103782

A General Framework for Weighted Gene Co-Expression Network Analysis

Bin Zhang, Steve Horvath. (2005). Statistical Applications in Genetics and Molecular Biology. Cited 4,805 times. https://doi.org/10.2202/1544-6115.1128

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

D. Slamon, B. Leyland-Jones, Steven Shak, et al.. (2001). The New England journal of medicine. Cited 4,674 times. https://doi.org/10.1056/NEJM200103153441101

The Consensus Molecular Subtypes of Colorectal Cancer

J. Guinney, R. Dienstmann, Xin Wang, et al.. (2015). Nature medicine. Cited 4,370 times. https://doi.org/10.1038/nm.3967

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

C. Karapetis, S. Khambata-Ford, D. Jonker, et al.. (2008). The New England journal of medicine. Cited 3,628 times. https://doi.org/10.1056/NEJMoa0804385

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

S. O’Brien, F. Guilhot, R. Larson, et al.. (2003). The New England journal of medicine. Cited 3,609 times. https://doi.org/10.1056/NEJMOA022457

Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium.

Toshiro Sato, D. Stange, M. Ferrante, et al.. (2011). Gastroenterology. Cited 3,307 times. https://doi.org/10.1053/j.gastro.2011.07.050

Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients

A. Zehir, R. Benayed, Ronak H. Shah, et al.. (2017). Nature medicine. Cited 2,867 times. https://doi.org/10.1038/nm.4333

Patient-derived organoids model treatment response of metastatic gastrointestinal cancers

G. Vlachogiannis, S. Hedayat, A. Vatsiou, et al.. (2018). Science. Cited 1,595 times. https://doi.org/10.1126/science.aao2774

Rescue Surgery for Unresectable Colorectal Liver Metastases Downstaged by Chemotherapy: A Model to Predict Long-term Survival

R. Adam, V. Delvart, G. Pascal, et al.. (2004). Annals of Surgery. Cited 1,557 times. https://doi.org/10.1097/01.sla.0000141198.92114.f6

A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity

Norman Sachs, J. Ligt, O. Kopper, et al.. (2018). Cell. Cited 1,556 times. https://doi.org/10.1016/j.cell.2017.11.010

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.

S. Kopetz, A. Grothey, R. Yaeger, et al.. (2019). The New England journal of medicine. Cited 1,010 times. https://doi.org/10.1056/NEJMoa1908075

Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine.

C. Pauli, B. Hopkins, D. Prandi, et al.. (2017). Cancer discovery. Cited 795 times. https://doi.org/10.1158/2159-8290.CD-16-1154

Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer.

Hervé Tiriac, P. Belleau, Dannielle D. Engle, et al.. (2018). Cancer discovery. Cited 775 times. https://doi.org/10.1158/2159-8290.CD-18-0349

Cancer modeling meets human organoid technology

D. Tuveson, H. Clevers. (2019). Science. Cited 738 times. https://doi.org/10.1126/science.aaw6985

Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer.

R. Yaeger, Walid K. Chatila, Marla D Lipsyc, et al.. (2018). Cancer cell. Cited 724 times. https://doi.org/10.1016/j.ccell.2017.12.004

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors

A. Mendes-Pereira, S. Martin, R. Brough, et al.. (2009). EMBO Molecular Medicine. Cited 666 times. https://doi.org/10.1002/emmm.200900041

Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients

S. Ooft, F. Weeber, K. Dijkstra, et al.. (2019). Science Translational Medicine. Cited 581 times. https://doi.org/10.1126/scitranslmed.aay2574

Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.

J. Franko, Q. Shi, C. Goldman, et al.. (2012). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Cited 553 times. https://doi.org/10.1200/JCO.2011.37.1039

Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.

J. Franko, Q. Shi, J. Meyers, et al.. (2016). The Lancet. Oncology. Cited 551 times. https://doi.org/10.1016/S1470-2045(16)30500-9

Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer.

Ye Yao, Xiaoya Xu, Li-feng Yang, et al.. (2019). Cell stem cell. Cited 544 times. https://doi.org/10.1016/j.stem.2019.10.010

A rectal cancer organoid platform to study individual responses to chemoradiation

K. Ganesh, Chao Wu, K. O’Rourke, et al.. (2019). Nature Medicine. Cited 428 times. https://doi.org/10.1038/s41591-019-0584-2

Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases

F. Weeber, M. van de Wetering, M. Hoogstraat, et al.. (2015). Proceedings of the National Academy of Sciences. Cited 409 times. https://doi.org/10.1073/pnas.1516689112

Patient derived organoids to model rare prostate cancer phenotypes

(2018). Nature Communications. Cited 310 times. https://doi.org/10.1038/s41467-018-04495-z

Oral Mucosal Organoids as a Potential Platform for Personalized Cancer Therapy.

E. Driehuis, S. Kolders, S. Spelier, et al.. (2019). Cancer discovery. Cited 290 times. https://doi.org/10.1158/2159-8290.CD-18-1522

Functional precision cancer medicine—moving beyond pure genomics

A. Letai. (2017). Nature Medicine. Cited 285 times. https://doi.org/10.1038/nm.4389

PTEN Deficiency in Endometrioid Endometrial Adenocarcinomas Predicts Sensitivity to PARP Inhibitors

K. Dedes, D. Wetterskog, A. Mendes-Pereira, et al.. (2010). Science Translational Medicine. Cited 258 times. https://doi.org/10.1126/scitranslmed.3001538

Organoids - Preclinical Models of Human Disease.

Mo Li, J. I. Izpisúa Belmonte. (2019). The New England journal of medicine. Cited 132 times. https://doi.org/10.1056/NEJMra1806175

Targeting EGFR in colorectal cancer.

W. Messersmith, D. Ahnen. (2008). The New England journal of medicine. Cited 130 times. https://doi.org/10.1056/NEJMe0806778

What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: A 25‐year experience with 1,125 procedures

G. Passot, D. Vaudoyer, L. Villeneuve, et al.. (2016). Journal of Surgical Oncology. Cited 127 times. https://doi.org/10.1002/jso.24248

Multicentric initial experience with the use of the pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the management of unresectable peritoneal carcinomatosis.

M. Alyami, J. Gagnière, O. Sgarbura, et al.. (2017). European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. Cited 110 times. https://doi.org/10.1016/j.ejso.2017.09.010

Neoadjuvant FOLFOX chemotherapy in 34 consecutive patients with mucinous peritoneal carcinomatosis of appendiceal origin

P. Sugarbaker, L. Bijelic, D. Chang, et al.. (2010). Journal of Surgical Oncology. Cited 106 times. https://doi.org/10.1002/jso.21679

Multicenter comprehensive methodological and technical analysis of 832 pressurized intraperitoneal aerosol chemotherapy (PIPAC) interventions performed in 349 patients for peritoneal carcinomatosis treatment: An international survey study.

M. Nowacki, M. Alyami, L. Villeneuve, et al.. (2018). European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. Cited 94 times. https://doi.org/10.1016/j.ejso.2018.02.014

Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy

I. Ubink, Ana C. F. Bolhaqueiro, S. Elias, et al.. (2019). The British Journal of Surgery. Cited 92 times. https://doi.org/10.1002/bjs.11206

Neoadjuvant Chemotherapy with Bevacizumab May Improve Outcome after Cytoreduction and Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) for Colorectal Carcinomatosis

W. Ceelen, Y. Nieuwenhove, D. V. Putte, et al.. (2014). Annals of Surgical Oncology. Cited 90 times. https://doi.org/10.1245/s10434-014-3713-7

Oxaliplatin versus Mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis.

V. Leung, Ya Ruth Huo, W. Liauw, et al.. (2017). European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. Cited 85 times. https://doi.org/10.1016/j.ejso.2016.09.015

Patient selection for cytoreductive surgery and HIPEC for the treatment of peritoneal metastases from colorectal cancer

G. Simkens, K. Rovers, S. Nienhuijs, et al.. (2017). Cancer Management and Research. Cited 69 times. https://doi.org/10.2147/CMAR.S119569

Colorectal Cancer: Prevention and Management of Metastatic Disease

P. Sugarbaker. (2014). BioMed Research International. Cited 63 times. https://doi.org/10.1155/2014/782890

Prognostic factors influencing survival in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for isolated colorectal peritoneal metastases: a systematic review and meta‐analysis

V. Narasimhan, Sabrina Tan, Joseph C. H. Kong, et al.. (2020). Colorectal Disease. Cited 59 times. https://doi.org/10.1111/codi.15003

Iterative cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: A multi‐institutional experience

N. Alzahrani, S. Valle, O. Fisher, et al.. (2018). Journal of Surgical Oncology. Cited 38 times. https://doi.org/10.1002/jso.25277

Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer

Chang Xu, Olga Nikolova, Ryan S Basom, et al.. (2018). Clinical Cancer Research. Cited 20 times. https://doi.org/10.1158/1078-0432.CCR-17-1339